DNA Vaccine Development for Pancreatic Cancer

DNA Vaccine Development for Pancreatic Cancer

DNA Vaccine Development for Pancreatic Cancer

Continuous developments in immuno-oncology have opened an unprecedented path for the emergence of vaccine strategies. Among them, therapeutic DNA cancer vaccines are simple, stable, and safe, and are considered an attractive immunotherapeutic approach to activate the immune system against cancer. Alfa Cytology is a leading custom service provider in PC vaccine research and development. We are committed to providing the best service in DNA vaccine development for PC and guaranteeing the best results for our customers worldwide.

Overview of DNA cancer vaccine

DNA-mediated immunizations began in the 1990s, initially for the treatment of influenza. Since then, DNA vaccines have been developed to treat a variety of diseases, including multiple cancers. DNA vaccines are based on bacterial plasmids encoding antigens and ultimately immunostimulatory molecules. Through different delivery strategies (including physical and chemical methods), DNA is transported into the nucleus overcoming extracellular and intracellular barriers. Once in the nucleus, the antigen encoded by the DNA vaccine needs to be expressed and presented on major histocompatibility molecules (MHC) to activate T cells. In addition to the intrinsic components of plasmid DNA that activate the innate immune response, the antigens encoded by DNA vaccines can also be presented via MHC class I and II, thereby activating CD4+ and CD8+ T-cells and indirectly activating humoral immunity.

Fig. 1 Innate and adaptive immune activation induced by DNA vaccines. (Lopes, Alessandra et al., 2021)Fig. 1 Innate and adaptive immune activation induced by DNA vaccines. (Lopes, Alessandra et al., 2021)

DNA vaccine development services for PC

During DNA vaccine development, we focus on the selection and optimization of optimal antigens to be inserted into plasmid DNA. This is an important step in DNA vaccine development, involving issues such as antigen loss, modification, and tolerance that can increase the immunogenicity of a DNA vaccine and thus trigger a broad immune response. In addition, based on our in-depth understanding of the tumor immunological profile of PC, we can help my clients to achieve precise and feasible development applications of PC DNA vaccines.

  • DNA vaccine preparation

DNA vaccine preparation includes the chemical synthesis of DNA encoding the antigen, bacterial fermentation to amplify recombinant plasmids, plasmid isolation and purification, and finally encapsulation into nanoparticles. Optimizing each part of this process is important to produce the highest yield and quality vaccines at the lowest cost.

-Plasmid design and selection

-Development of DNA vaccine production process, such as fermentation development and formulation development

-DNA vaccine quality control

  • DNA vaccine validation

- in vitro assay

- in vivo animal assay

-Selection of optimal regimens (dose, schedule, and administration route)

-Feasible and immunogenic evaluation of DNA vaccines

-Stability analysis of DNA vaccines

-Safety and efficacy evaluation of DNA vaccines

To provide DNA vaccines that enhance vaccine-induced immune response and treatment efficacy, we focus on three major directions, including the rational selection of coding antigens, optimization of suitable antigens for insertion into plasmid DNA, and provision of comprehensive and reliable preclinical validation studies. If you are interested in learning more about our PC vaccine development services, would like to learn more about our services and opportunities to participate in market research, or are interested in a potential partnership or collaboration, please don't hesitate to contact us.


  1. Lopes, Alessandra, Gaëlle Vandermeulen, and Véronique Préat. "Cancer DNA vaccines: current preclinical and clinical developments and future perspectives." Journal of Experimental & Clinical Cancer Research 38.1 (2019): 1-24.
  2. Cappello, Paola, et al. "Next generation immunotherapy for pancreatic cancer: DNA vaccination is seeking new combo partners." Cancers 10.2 (2018): 51.
All of our services are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.